You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四环医药(00460.HK)购美药厂新一代氨基糖(甘)类抗生素之大中华区权益
阿思达克 02-20 16:49
四环医药(00460.HK)公布,附属全资子公司「轩竹」已收购於美国特拉华州注册成立的公司Achaogen於大中华区(包括中国内地及港澳台)有关新一代氨基糖(甘)类抗生素plazomicin的所有权益及知识产权。 Plazomicin是由Achaogen开发的新一代半合成氨基糖(甘)类抗生素,主要通过与细菌核糖体30S亚基结合,产生抑菌作用,开发用於治疗多药耐药(MDR)革兰氏阴性菌肠杆菌科细菌导致的严重感染,包括对碳青霉烯类抗生素耐药的肠杆菌。在中国,MDR菌感染途径主要为医院获得性感染,受感染者多为各种原因导致的免疫力低下者。如新型冠状病毒等病毒感染後,会侵犯淋巴细胞破坏人体的免疫系统,当人体的免疫力降低时便有可能出现继发细菌感染,增加医院获得性进一步感染机会。 据医药市场调研机构Evaluate Pharma预测,plazomicin的年销售额在2022年将达到3.13亿美元。而在大中华区上市後,集团预期plazomicin将带来可观的经济收益。(ic/da)~ 阿思达克财经新闻 网址: www.aastocks.com
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account